 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- | Keytruda (pembrolizumab) / Merck (MSD), Isturisa (osilodrostat) / Novartis, Recordati
Journal: Pembrolizumab-induced cyclic ACTH-dependent Cushing's syndrome treated by a block-and-replace approach with osilodrostat. (Pubmed Central) - Mar 23, 2022
No abstract available